Mostrar el registro sencillo del ítem

Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial

dc.creatorRomo-Nava, F.
dc.creatorGonzalez, D. A. I.
dc.creatorFresan-Orellana, A.
dc.creatorAlvarez, R. S.
dc.creatorBecerra-Palars, C.
dc.creatorMoreno, J.
dc.creatorUribe, M. P. O.
dc.creatorBerlanga, C.
dc.creatorHeinze, G.
dc.creatorBuijs, R. M.
dc.date.accessioned2017-06-29T03:57:55Z
dc.date.available2017-06-29T03:57:55Z
dc.date.issued2014es_ES
dc.identifier2813es_ES
dc.identifier.issn1398-5647es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/4662
dc.identifier.urihttps://doi.org/10.1111/bdi.12196es_ES
dc.language.isoenges_ES
dc.publisherCopenhagen : Wiley-Blackwell Munksgaardes_ES
dc.relation16 (4) 410-421 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleMelatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical triales_ES
dc.typeartículoes_ES
dc.contributor.affiliationDepartamento de Psiquiatria y Salud Mental, Facultad de Medicina, UNAM, Mexicoes_ES
dc.contributor.emailruudbuijs@gmail.comes_ES
dc.relation.jnabreviadoBIPOLAR DISORDes_ES
dc.relation.journalBipolar Disorderses_ES
dc.identifier.placeDinamarcaes_ES
dc.date.published2014es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.eissn1399-5618es_ES
dc.identifier.doi10.1111/bdi.12196es_ES
dc.description.monthJunes_ES
dc.description.abstractotrodiomaOBJECTIVE:  Second-generation antipsychotics (SGAs) are among the first-line treatments for bipolar disorder and schizophrenia, but have a tendency to generate metabolic disturbances. These features resemble a metabolic syndrome for which a central autonomic imbalance has been proposed that may originate from the hypothalamic suprachiasmatic nuclei. In a clinical trial, we hypothesized that melatonin, a hormone that regulates the suprachiasmatic nucleus, could attenuate SGA-induced adverse metabolic effects. METHODS:  In an eight-week, double-blind, randomized, placebo-controlled, parallel-group clinical trial, we evaluated the metabolic effect of melatonin in SGA-treated patients in terms of weight, blood pressure, lipid, glucose, body composition, and anthropometric measures. A total of 44 patients treated with SGAs, 20 with bipolar disorder and 24 with schizophrenia, randomly received placebo (n = 24) or melatonin 5 mg (n = 20). RESULTS:  The melatonin group showed a decrease in diastolic blood pressure (5.1 versus 1.1 mmHg for placebo, p = 0.003) and attenuated weight gain (1.5 versus 2.2 kg for placebo, F = 4.512, p = 0.040) compared to the placebo group. The strong beneficial metabolic effects of melatonin in comparison to placebo on fat mass (0.2 versus 2.7 kg, respectively, p = 0.032) and diastolic blood pressure (5.7 versus 5.5 mmHg, respectively, p = 0.001) were observed in the bipolar disorder and not in the schizophrenia group. No adverse events were reported. CONCLUSIONS:  Our results show that melatonin is effective in attenuating SGAs' adverse metabolic effects, particularly in bipolar disorder. The clinical findings allow us to propose that SGAs may disturb a centrally mediated metabolic balance that causes adverse metabolic effects and that nightly administration of melatonin helps to restore. Melatonin could become a safe and cost-effective therapeutic option to attenuate or prevent SGA metabolic effects.  es_ES
dc.subject.koBipolar Disorderes_ES
dc.subject.koBlood Pressurees_ES
dc.subject.koFat Masses_ES
dc.subject.koMelatonines_ES
dc.subject.koMetabolices_ES
dc.subject.koSchizophreniaes_ES
dc.subject.koSecond-Generation Antipsychotices_ES
dc.subject.koWeightes_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem